Candel Therapeutics, Inc. (CADL) earnings date
Mar 18, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 10% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 13 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | after close | 43 | 8-K |
| Q2 FY2026 | Thu, Aug 13, 2026 | before open | 44 | 8-K |
| Q1 FY2026 | Thu, May 14, 2026 | before open | 44 | 8-K |
| Q4 FY2025 | Thu, Mar 12, 2026 | before open | 71 | 8-K |
| Q3 FY2025 | Thu, Nov 13, 2025 | before open | 44 | 8-K |
| Q2 FY2025 | Thu, Aug 14, 2025 | before open | 45 | 8-K |
| Q1 FY2025 | Tue, May 13, 2025 | before open | 43 | 8-K |
| Q4 FY2024 | Thu, Mar 13, 2025 | after close | 72 | 8-K |
What they guided beta
| Q3 FY2026 | "Cash and cash equivalents of $203.1 million, as of September 30, 2026, are expected to be sufficient to fund the Company’s current operating plan into Q2 2028." exhibit |
| Q3 FY2026 | "Based on current operating plans, the Company expects that its existing cash and cash equivalents, as of September 30, 2026, will be sufficient to fund operations into Q2 2028." exhibit |
| Q2 FY2026 | "Cash and cash equivalents of $201.6 million, as of June 30, 2026, are expected to be sufficient to fund the Company’s current operating plan into Q1 2028, which includes activities to support the potential commercial launch of aglatimagene in 2027 NEEDHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced financial results for the second quarter ended June 30, 2026, and provided a corpo" exhibit |
| Q2 FY2026 | "The Company expects to present potential long-term survival data from arm C of its phase 1b clinical trial of linoserpaturev in patients with recurrent high-grade glioma (rHGG) in Q4 2026." exhibit |
| Q2 FY2026 | "Based on current operating plans, the Company expects that its existing cash and cash equivalents, as of June 30, 2026, will be sufficient to fund operations into Q1 2028." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CADL
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CADL
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/CADL/"><img src="https://veritasdata.dev/embed/CADL.svg" alt="CADL earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/CADL/)
Script
<script async src="https://veritasdata.dev/embed/CADL.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CADL"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.